An Endotracheal Plasmablastic Lymphoma by Bots, E.M.T. (Eva) et al.
Novel Insights from Clinical Practice
Respiration
An Endotracheal Plasmablastic 
Lymphoma
Eva M.T. Bots a, b    Johan Opperman c    Fatima Bassa d    
Coenraad F.N. Koegelenberg a    
a
 Division of Pulmonology, Department of Medicine, Stellenbosch University and Tygerberg Hospital,  
Cape Town, South Africa; b Pulmonology Department, Erasmus Medical Centre, Rotterdam, The Netherlands; 
c
 Division of Anatomical Pathology, Department of Pathology, National Health Laboratory Service and  
Stellenbosch University, Cape Town, South Africa; d Division of Haematology, Department of Medicine,  
Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa
Received: August 6, 2019
Accepted: September 20, 2019
Published online: October 21, 2019
Eva Marianne Theresa Bots
Erasmus MC Longgeneeskunde
Erasmus Medical Centre
Postbus 2040, NL–3000 CA Rotterdam (The Netherlands)
E-Mail e.bots @ erasmusmc.nl
© 2019 The Author(s)
Published by S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com/res
Established Facts
• Tracheal tumours encompass a small proportion of respiratory tract neoplasms, and tracheal lympho-
mas are very rare.
• Endotracheal plasmablastic lymphoma has never been described.
Novel Insights 
• Plasmablastic lymphomas can involve the trachea.
• Macroscopically, endotracheal plasmablastic lymphoma is indistinguishable from other more com-
mon causes of tracheal tumour occurrence.
DOI: 10.1159/000503586
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Abstract
We describe an exceptionally rare case of a male patient with 
newly diagnosed advanced human immunodeficiency virus 
(HIV) infection, who presented with a plasmablastic lympho-
ma involving the right maxillary alveolar ridge with associ-
ated cervical lymphadenopathy. On a staging positron emis-
sion tomography computed tomography (PET-CT) scan, he 
was incidentally found to have an endotracheal tumour in-
volving the anterolateral aspect of the mid-trachea. The tu-
mour appeared to be well-vascularised at bronchoscopy and 
was confirmed as well-differentiated plasmablastic lympho-
ma. Plasmablastic lymphoma is a rare form of non-Hodgkin 
lymphoma and is associated with HIV. Tracheal involvement 
to the extent seen in our patient is exceptionally rare, and, to 
the best of our knowledge, has never been described.
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Introduction
Tracheal tumours encompass a small proportion of re-
spiratory tract neoplasms, accounting for only about 2% 
of airway malignancies and with an incidence of 0.1 per 
100,000 people per year [1]. Squamous-cell carcinoma is 
the most common tracheal tumour, followed by adenoid 
cystic carcinoma [1]. Symptoms are usually attributable 
to the intraluminal component of the tumour causing ob-
struction of the airway with stridor, dyspnoea, wheezing, 
haemoptysis, and cough.
The true incidence of secondary tracheal tumours, de-
fined as tumours within the trachea but which do not 
originate from the trachea, is unknown. Tracheal involve-
ment may occur because of direct invasion, or hematog-
enous or lymphatic spread, and the most common aeti-
ologies are thyroid cancer, oesophageal tumour, and 
squamous-cell carcinoma of the lung [2].
Endotracheal lymphoma, albeit rare, has been report-
ed, particularly polypoid nodules secondary to mucosa-
associated lymphoid tissue (MALT) lymphoma [3].
Case Report
A 40-year-old male smoker without any significant medical 
history presented with a 2-month history of a soft-tissue swell-
ing of the right maxillary area, which persisted after teeth extrac-
tions. He was found to have a large ulcerative lesion involving 
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Fig. 1. a Biopsy of the maxillary lesion showed tumour cells exhib-
iting predominantly immunoblastic differentiation with focal 
plasmablastic differentiation. The tumour cells showed strong im-
munoreactivity with plasma cell-associated antigens CD138, 
MUMI, EMA, and CD38, variable positivity with the B cell mark-
ers CD45 and CD79a, and was completely negative for CD20, all 
compatible with a high-grade B cell non-Hodgkin lymphoma, par-
ticularly plasmablastic lymphoma. Cytoplasmic κ light chain re-
striction and EBV were present. a Maxillary tumour with oral mu-
cosa with a submucosal tumour. ×200. b Submucosal infiltrate 
comprising sheets of immunoblastic cells exhibiting immunoreac-
tivity with CD138. c Nuclear positivity with EBER-in situ hybrid-
ization. d Cytoplasmic κ light chain restriction. ×400.
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the right maxillary alveolar ridge, with associated cervical 
lymphadenopathy. A biopsy of the maxillary lesion showed plas-
macytic differentiation, with tumour cells exhibiting strong im-
munoreactivity, variable positivity with B cell markers, cytoplas-
mic κ light chain restriction, and the presence of Epstein-Barr 
virus (EBV, Fig. 1), all compatible with a diagnosis of high-grade 
B cell non-Hodgkin lymphoma (NHL), in particular plasma-
blastic lymphoma.
The patient was referred to our institution and subsequently 
found to be positive for human immunodeficiency virus (HIV) 
with a CD4 count of 69 cells/mm3. He was anti-retroviral therapy 
(ART)-naïve.
Routine staging positron emission tomography computed to-
mography (PET-CT) was performed and showed intense 18F-la-
belled fluoro-2-deoxyglucose (FDG) uptake in the known right 
maxillary tumour (Fig. 2a), with associated bony destruction. An 
endotracheal tumour measuring 14 × 11 mm (Fig. 2b), with less 
intense FDG uptake, was also noted. In view of the differential 
FDG uptake, a biopsy was advised.
The tumour appeared to be well-circumscribed and vascular-
ised at bronchoscopy, with an appearance compatible with a pri-
mary tracheal tumour (Fig. 2c). Conventional fine-needle aspira-
tion of the tumour did not yield diagnostic material (on rapid on-
site evaluation), and forceps biopsies were subsequently 
cautiously obtained.
The histology of the endotracheal lesion also showed plasma-
cytic differentiation, with tumour cells exhibiting strong immuno-
reactivity with plasma cell-associated antigens as noted in the max-
illary tumour, variable positivity with B cell markers, and the pres-
ence of EBV, all compatible with a diagnosis of plasmablastic 
lymphoma (Fig.  3). Of interest is the fact that the endotracheal 
tumour cells were more mature, with plasmacytic differentiation.
The levels of bone marrow aspirate, trephine, and serum cal-
cium as well as renal function were normal, and the serum protein 
electrophoresis revealed a small polyclonal band. The patient was 
commenced on combination chemotherapy and ART, and has had 
a good clinical response to date.
Discussion
Of people living with HIV, up to 40% will develop ma-
lignancy, with approximately 10% developing NHL [4, 5]. 
The most common systemic NHL subtypes seen in HIV-
positive individuals are diffuse large B cell lymphoma 
(75%) and Burkitt lymphoma [6].
Plasmablastic lymphoma accounts for < 3% of NHL 
seen in HIV-positive patients [7, 8]. It is a rare form of 
NHL that usually occurs in the oral cavity and these indi-
viduals are often positive for EBV [9, 10]. Involvement of 
the paranasal sinuses, skin, soft tissue, larynx, lung, and 
anorectal region have been described [11]. Tracheal in-
volvement is exceptionally rare, and, to the best of our 
knowledge, has never been described.
Co-infection with Human herpesvirus 8 has also been 
reported in plasmablastic lymphoma, with a prevalence 
a
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Fig. 2. a Staging PET-CT scan showed intense FDG uptake in the 
known right maxillary tumour, with associated destruction of the 
right maxillary bone but no evidence of intracranial extension. 
b It also showed a soft-tissue mass with mild FDG uptake involv-
ing the anterolateral aspect of the mid trachea. c At bronchoscopy, 
a well-vascularised tumour was seen with no other endobronchial 
abnormalities.
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ranging from 17 to 100% [12, 13]. Another rare genetic 
subtype of plasmablastic lymphoma has rearrangements 
of the ALK tyrosine kinase gene.
A review of 157 cases of plasmablastic lymphoma re-
ported that early clinical stage and complete response to 
chemotherapy are associated with a better outcome. The 
best approach to therapy remains unclear, and standard 
CHOP (cyclophosphamide, hydroxydaunorubicin [Adri-
amycin], vincristine [Oncovin], and prednisone or pred-
nisolone) is considered an inadequate therapy [14]. The 
American National Comprehensive Cancer Network 
guidelines recommend a more intensive regimen, as at 
least 1 study has suggested better outcomes using more 
aggressive chemotherapy such as that used for Burkitt 
lymphoma [15].
In conclusion, plasmablastic lymphoma is an extreme-
ly rare form of HIV-related lymphoma, and endotracheal 
involvement is with plasmablastic lymphoma is not typi-
cally seen, which makes this possibly the first properly 
documented case.
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Fig. 3. The histology of the endotracheal lesion also showed plasmacytic differentiation, with tumour cells 
exhibiting strong immunoreactivity with plasma cell-associated antigen CD138, MUMI, EMA, and CD38, but 
variable positivity with the B cell markers CD45 and CD79a, and completely negative for CD20. The endo-
tracheal tumour cells differed cytomorphologically from the oral cavity tumour, showing a more mature plas-
macytic differentiation. a Respiratory-type mucosa with a submucosal tumour. ×200. b Submucosal infiltrate 
comprising of sheets of cells with a plasmacytic differentiation, exhibiting immunoreactivity with CD138 (c) 
and positive for EBER-in situ hybridization (d; ×400).
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